UK computational chemistry SME providing molecular modeling expertise for ocular, CNS, and oncology drug discovery programs.
Cresset Biomolecular Discovery is a UK-based computational chemistry company that develops software and provides expert services for molecular modeling and drug discovery. Their core business is helping pharmaceutical and biotech clients find and optimize drug candidates by predicting how small molecules interact with biological targets — using field-based and structure-based computational methods. In their H2020 participations, they contributed this specialist computational capability to multi-partner consortia working on oncology, ophthalmic, and CNS drug programs. As an MSCA-RISE partner, they also engaged in staff exchange with academic groups, embedding their drug discovery tools into cutting-edge research workflows.
Both 3D NEONET and CRYSTAL3 are drug discovery projects where Cresset's specialist computational chemistry role is the clear value-add in a consortium otherwise dominated by academic and clinical partners.
Both projects explicitly target eye conditions — 3D NEONET covers eye therapeutics alongside oncology, and CRYSTAL3 focuses specifically on ocular dysfunction via cysteinyl leukotriene signaling.
3D NEONET (2017–2022) addressed drug discovery and delivery for oncology as a primary disease area alongside eye therapeutics.
CRYSTAL3 (2021–2024) targets cysteinyl leukotriene signaling in CNS dysfunction, extending Cresset's involvement into the neurological disease space for the first time.
Both projects lack keyword metadata, so the evolution must be read from project scope and timing. The earlier engagement (3D NEONET, 2017) was deliberately broad — spanning two disease areas (oncology and ophthalmology) with a network-building focus typical of early MSCA-RISE involvement. The more recent project (CRYSTAL3, 2021) is sharply more specific: a defined molecular target (cysteinyl leukotriene receptors), a defined clinical indication cluster (ocular and CNS dysfunction), and an explicit commercial angle embedded in the acronym itself. This points to a company moving from broad multi-disease exposure toward mechanism-specific, clinically grounded discovery work with clearer commercialization intent.
Cresset is narrowing toward specific receptor targets and dual-indication (eye + CNS) programs, suggesting future collaborations will likely center on mechanistic computational work where their software can accelerate target-specific hit identification.
Cresset has participated in both projects as a non-coordinating partner, indicating a preference for contributing specialist expertise rather than managing consortium logistics. Both engagements were under MSCA-RISE, a scheme built on staff exchange, which means Cresset operates as a knowledge node — sending and receiving researchers — rather than as a project driver. Their per-project partner count (~14 on average across both) places them in large, diverse consortia where their computational niche is one piece of a bigger research chain.
Cresset has co-participated with 28 unique partners across 10 countries from just 2 projects — an unusually high partner density for such a small portfolio, reflecting the large-consortium structure of MSCA-RISE schemes. Their network is pan-European with likely strong links to UK, Southern European, and Eastern European academic medical centers typical of eye and CNS research consortia.
Cresset occupies a rare position in European H2020 networks as a private computational chemistry SME that bridges software tooling and applied drug discovery in specialized therapeutic niches — specifically ophthalmology and CNS. Most computational chemistry input in H2020 consortia comes from academic groups; a commercial software provider with its own IP in the room brings a different kind of credibility and post-project commercialization potential. For consortium builders, they offer a direct route to proprietary molecular modeling platforms without going through academic licensing bottlenecks.
